StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Mallinckrodt (MNK) Announces Completion of Hemostasis Drug Portfolios Acquisition from Medicines Co. (MDCO)
February 1, 2016 8:51 AM
Mallinckrodt plc (NYSE: MNK) announced it closed the acquisition of the global portfolio of three commercial-stage topical hemostasis drugs from ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Mergers and Acquisitions
Spinoffs
Next Articles
Piper Jaffray Reiterates Overweight on Mallinckrodt (MNK) Following Solid 1Q Results
February 3, 2016 8:58 AM
Mallinckrodt Completes Acquisition Of Three Commercial-Stage, Global Specialty Hemostasis Brands From The Medicines Company
February 1, 2016 8:50 AM